CD79A and rheumatoid arthritis: A study using the U.S. Department of Defense Serum Repository reported that circulating anti-MAA antibody (IgA and IgG) levels began to diverge from those of controls approximately 2.3 years and 3 years before the clinical onset of RA, respectively (31).